Navigation Links
U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
Date:11/8/2010

MELBOURNE, Australia, Nov. 8, 2010 /PRNewswire/ -- Regenerative medicine company, Mesoblast Limited (ASX: MSB; USADR: MBLTY), today announced that its United States associate company, Angioblast Systems, has been awarded $1.2 million in grants under the United States Government's Qualifying Therapeutic Discovery Project (QTDP) program.

Angioblast received the maximum grant amount awarded for each of the five projects that were eligible for QTDP funding.  The projects, selected jointly by the United States Treasury Department and the Department of Health and Human Services, relate to the company's adult stem cell products for congestive heart failure, heart attack, oncology, eye and diabetes indications.

"We are pleased to have received this cash award, and will use the funds to advance our objectives for product commercialization," said Mesoblast Chief Executive Professor Silviu Itescu.

The QTDP program was enacted as part of the Patient Protection and Affordable Care Act of 2010 to provide tax credits to eligible companies in order to encourage investments in new therapies for prevention or treatment of acute and chronic diseases.  Companies, such as Angioblast Systems, that cannot currently use a tax credit were allowed to apply for a cash grant in lieu of a tax credit.

To be eligible for the program, projects had to show reasonable potential to result in new therapies to treat areas of unmet medical need, prevent, detect, or treat chronic or acute disease and conditions, or reduce long-term health care costs in the United States.  Preference was given to projects that showed the greatest potential to create and sustain (directly or indirectly) high quality, high-paying jobs in the United States, and advance United States competitiveness in the fields of life, biological, and medical sciences.

"The award serves as further external recognition, in this case by the United States Government, of the strength and promise of our adult stem cell technology platform to deliver effective therapies for a range of conditions currently in great medical need," said Professor Itescu.

About Mesoblast

Mesoblast Limited (ASX: MSB; USADR: MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.comContact:Julie MeldrumMesoblast Limited+61 3 9639 6036    julie.meldrum@mesoblast.com
'/>"/>

SOURCE Mesoblast Limited
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
3. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
4. BioSpec Global Solutions Inc hopes to receive confirmation from Chinese government for testing of TOGS™ 9000
5. Curemark Attends North American Bio Forum at Canadian Government Invitation
6. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
7. The Irish Government and the Irish Voice Recognize Fibrocell Science, Inc.s Declan Daly as Irish Life Science 50 Member
8. AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award
9. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
10. Brazilian Sugarcane Industry Association Stresses Need for Brazils Government to Announce Ethanol Import Tariff Cut as Soon as Possible
11. North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):